Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly oral islatravir + lenacapavir vs daily Biktarvy in virologically suppressed adults with HIV-1
jRCT2051240217Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of islatravir and lenacapavir in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48. Started Jan 2025; status: active, not recruiting.
02
Drugs
islatravirlenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2051240217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240217.